| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZBED1 |
| Uniprot No | O96006 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3-100aa |
| 氨基酸序列 | NKSLESSQTDLKLVAHPRAKSKVWKYFGFDTNAEGCILQWKKIYCRICMA QIAYSGNTSNLSYHLEKNHPEEFCEFVKSNTEQMREAFATAFSKLKPE |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ZBED1重组蛋白的模拟参考文献示例，格式包含文献名称、作者及摘要概括：
1. **文献名称**: *"Expression and Purification of Recombinant ZBED1 Protein in Escherichia coli for Functional Studies"*
**作者**: Zhang L, et al.
**摘要**: 本研究成功构建了ZBED1基因的原核表达载体，通过大肠杆菌系统高效表达并纯化具有活性的重组ZBED1蛋白。实验验证该蛋白可在体外结合特定DNA序列，为后续功能研究奠定基础。
2. **文献名称**: *"Structural Insights into ZBED1’s DNA-Binding Domain via Crystallography of Recombinant Protein"*
**作者**: Kim S, Patel R.
**摘要**: 利用重组ZBED1蛋白的晶体结构解析，揭示了其BED结构域与锌指基序协同作用结合DNA的分子机制，为理解其在基因调控中的功能提供结构依据。
3. **文献名称**: *"ZBED1 Recombinant Protein Modulates Chromatin Accessibility in Mouse Embryonic Stem Cells"*
**作者**: García-Martínez V, et al.
**摘要**: 通过体外重组ZBED1蛋白处理小鼠胚胎干细胞，发现其通过改变染色质开放状态影响多能性基因表达，提示其在表观遗传调控中的潜在作用。
4. **文献名称**: *"Development of a ZBED1-Specific Monoclonal Antibody Using Recombinant Protein as Immunogen"*
**作者**: Wang H, et al.
**摘要**: 以纯化的重组ZBED1蛋白为抗原制备单克隆抗体，验证了抗体的高特异性与灵敏度，为ZBED1的细胞定位及蛋白互作研究提供了关键工具。
注：以上文献及内容为模拟生成，实际研究请参考真实学术数据库(如PubMed/Web of Science)。
ZBED1 (zinc finger BED domain-containing protein 1) is a conserved eukaryotic protein that plays critical roles in transcriptional regulation, chromatin remodeling, and developmental processes. Structurally, it contains a characteristic BED (BEAF and DREF) domain, a zinc finger motif enabling DNA binding, and nuclear localization signals. Initially identified through homology with the Drosophila BEAF-32 protein, ZBED1 has been implicated in regulating gene clusters, including histone genes and proto-oncogenes, by binding to specific DNA sequences at promoter regions.
The recombinant ZBED1 protein is engineered for functional studies, typically expressed in E. coli or mammalian systems with affinity tags (e.g., GST, His-tag) for purification. This allows researchers to investigate its DNA-binding specificity, protein-protein interactions, and regulatory mechanisms in vitro. Studies using recombinant ZBED1 have revealed its dual role as both a transcriptional repressor and activator, depending on cellular context and post-translational modifications. It interacts with chromatin-modifying complexes like HDACs and Polycomb group proteins, suggesting involvement in epigenetic regulation.
Emerging evidence links ZBED1 to human diseases. Its dysregulation has been observed in cancers, particularly hepatocellular carcinoma and gliomas, where it may influence tumor progression through cell cycle modulation. Additionally, ZBED1 knockout models display embryonic lethality in mice, underscoring its essential role in early development. Current research leverages recombinant ZBED1 to dissect its molecular functions and explore therapeutic targeting potential. However, its precise mechanism of action and full spectrum of target genes remain active areas of investigation, highlighting the importance of recombinant protein tools in advancing this field.
×
